First Generics of Afinitor Approved

The FDA approved the first two generics of Novartis’ cancer drug Afinitor (everolimus) by Teva and Par Pharmaceuticals.

Both companies gained approval for everolimus tablets in 2.5 mg, 5, mg, and 7mg doses. Teva also picked up an additional approval for the drug in a 10 mg dose.

Novartis earned approximately $1.6 billion from sales of Afinitor in fiscal 2018, according to the drugmaker’s financial report.